news aktuell GmbH

Hankook iON Winter: nytt vinterdäck för elfordon

Dela

Neu-Isenburg, Tyskland, 29 september 2022 – Efter iON evo, Hankooks sommardäck, är det nya vinterdäcket Hankook iON Winter den andra medlemmen i den nya, globala däckfamiljen "iON" speciellt utformat för elfordon. Tillverkaren av premiumdäck syftar alltså till att främja elektrisk mobilitet även under den kalla årstiden.

Hankook iON Winter - the new winter tyre specifically developed for electric vehicles (EVs)
Hankook iON Winter - the new winter tyre specifically developed for electric vehicles (EVs)

Det nya däckets egenskaper inkluderar minskat rullmotstånd och lågt buller från däcket vid körning. I jämförelse med traditionella däck innebär det här längre räckvidd per batteriladdning samt en mer komfortabel och bättre körupplevelse. Hankooks iON-produkter är dessutom speciellt utformade för att hantera, höga vridmomentet hos kraftfulla elfordon.

En speciell utmaning: vinterdäck för elbilar

Hankook iON Winter har en specialutvecklad slitbaneblandning som säkerställer lägsta möjliga rullmotstånd utan att ge avkall på prestanda på våta och snötäckta vägar. Naturliga oljor säkerställer det nödvändiga greppet, även vid låga temperaturer. Den exceptionella flexibiliteten gör att däcket anpassar sig till vägbanan och minimerar rörelser i profilen.

Buller från däcket vid körning är en speciell utmaning för vinterdäck. Den nya slitbanedesignen minskar märkbart buller som uppkommer på grund av den aktiva styrningen av ljudvågor. Den integrerade sound absorber™-tekniken minskar också ljudnivån inuti bilen. Samtidigt undviker aerodynamisk optimering ytterligare luftturbulens och minskar luftmotståndet. Detta har en positiv inverkan på både bullergenerering och räckvidd. Den höga halten silica ger ett väggrepp som motverkar att en farlig vattendyna bildas mellan vägyta och däck.

Hankook iON Winter kommer att finns tillgängligt i dimensioner från 18 till 22 tum.

Komplett presskit: www.hankooktire-mediacenter.com

- Bild och video finns på Presseportal -

Kontakt:

Larissa Büsch

PR Manager

+49 6102 8149-173

l.buesch@hankookn.com

Bilder

Hankook iON Winter - the new winter tyre specifically developed for electric vehicles (EVs)
Hankook iON Winter - the new winter tyre specifically developed for electric vehicles (EVs)
Ladda ned bild
Ladda ned bild

Om

news aktuell GmbH
news aktuell GmbH
Mittelweg 144
20148 Hamburg

+49 (0)40 4113-32589http://www.newsaktuell.de

As wholly owned subsidiary of dpa, news aktuell provides business and organizations with effective access to media and consumers. Via the smart tools ots and zimpel, PR content accesses all media formats, including classical print, high click-rate online portals and social networks. In addition, news aktuell publishes all its customers’ PR content on www.presseportal.de, one of the PR portals with the greatest reach in Germany. By this means, all the relevant multipliers are reached globally, from editors, via digital influencers right up to specialist bloggers and interested consumers. news aktuell has been on the market since 1989. The company, with a staff complement of more than 135, has its headquarters in Hamburg. Other offices are in Berlin, Dusseldorf, Frankfurt und Munich.

Följ news aktuell GmbH

Abonnera på våra pressmeddelanden. Endast mejladress behövs och den används bara här. Du kan avanmäla dig när som helst.

Senaste pressmeddelandena från news aktuell GmbH

Flu tests from R-Biopharm also detect new virus variants25.11.2022 10:46:20 CET | Press release

Darmstadt, November 25, 2022 – The flu season has begun and different virus variants are also circulating in Germany. With the flu tests from biotechnology company R-Biopharm, patients quickly have certainty: Its RIDA®GENE Flu assays also reliably detect the two novel variants. The company made the announcement with regard to influenza A H1N1pdm09, which is circulating primarily in the United Kingdom, and the H3N2 subtype, which was rampant in Denmark in the spring and is currently dominating influenza activity in Germany. "Mutations in the target gene (MP gene) can affect the diagnostic performance of influenza screening assays, producing false-negative test results," explains Dr. Andreas Simons, Head of Product Management at R-Biopharm. " Alignments of the detection systems we used with the described sequences of the two novel virus variants showed no mismatches. Their reliable detection is not affected by the described mutations." This means laboratories can continue to reliably con

THE HIGH-PERFORMANCE SINGLE-SEATER 777 HYPERCAR IS BORN IN MONZA22.11.2022 11:05:00 CET | Press release

The 777 hypercar is a new Italian hypercar born of the excellent partnership with Andrea Levy, Dallara, and Gibson, built from technology used in motorsports and all informations and images are on www.777hypercar.com. 777 hypercar is built by 777 Motors, the car manufacturer based in the Autodromo Nazionale Monza and founded by Andrea Levy, an entrepreneur, car collector, racing driver, and president of MIMO Milano Monza Motorshow. The 777 hypercar project will be presented on November 22, limited to just 7 units, each of which will cost 7 million euros. 777 hypercar is at the top for performance thanks to an FIA-homologated carbon monocoque developed by Dallara, which generate an incredible downforce of 2,100 kg at a speed of 370 km/h, an extremely low weight of 900 kg, and a lateral acceleration from 3.5 to 4 g that keeps the car glued to the asphalt, giving an incredible estimate lap time of just 1 minute and 33 seconds in the Monza Circuit. The engine is a naturally aspirated V8, 4

Janneke van der Kamp joins Grünenthal as new Chief Commercial Officer22.11.2022 11:01:42 CET | Press release

AACHEN, Germany, 22 November 2022 –Grünenthal today announced that Janneke van der Kamp will join Grünenthal as the new Chief Commercial Officer (CCO), effective 1 March 2023. Janneke van der Kamp joins Grünenthal from Novartis, where she most recently served as Head of Pharma Region Europe. The Dutch native brings broad experience in the pharmaceutical industry from several roles including General Manager, Global Neurosciences Franchise Head and Global Head of Product and Portfolio Strategy for the entire Novartis Pharma portfolio. She worked closely with Research & Development and the Licensing & Acquisitions teams to strengthen the company’s pipeline. Janneke van der Kamp has vast expertise in launching and growing key brands across several disease areas. She is a studied chemist and holds an MBA from INSEAD. As CCO of Grünenthal, Janneke van der Kamp will be responsible for the entire Global Commercial Organisation and serve as a member of the Corporate Executive Board. Her focus w

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum